Targazyme Incis A San Diego Basedclinical Stage Biopharmaceutical Company Developing Novel Enzyme Based Platform Technologies And Products To Improve Clinical Efficacy And Cost Of Care Outcomes For Cell Therapyimmunotherapies For Autoimmune Diseases And Cancerstem Cell Transplantationgene Therapy And Regenerative Medicine The Company S Clinical Grade Fucosyltransferase Enzymes And Small Molecule Productstz101 And Tz102Are Off The Shelf Biologic Products Used At The Point Of Care To Treat Therapeutic Cells Immediately Before Infusion Into The Patient Using A Simple Procedure That Is Easily Incorporated Into Existing Medical Practice The Company Has Received Worldwide Patentsmultiple Fda Orphan Drug Designationshas An Open Investigational New Drug Applicationindwith Multiple Ongoing Clinical Studies And A Phase 3 Special Protocol Assessmentspawith The Fdatargazyme S Fucosylation Technology Has Received Numerous Medical And Scientific Awards From Institutions Such As Nihncius Treasurycpritetfocastjdrfleukemialymphoma Society Targazyme Has Partnerships And Collaborations With Kyowa Hakko Kirin And Florida Biologixas Well As Various Medical Research Institutions Including The University Of Texas M Danderson Cancer Centeroklahoma Medical Research Foundationtexas Transplant Institutecase Western University Hospitalsscripps Hospitalsfred Hutchinson Cancer Research Centeruniversity Of California Los Angeles Medical Centerstanford University Medical Centeruniversity Of Minnesota Medical Centeruniversity Of California San Diego Medical Centersanford Burnham Medical Research Instituteindiana Universitymemorial Sloan Kettering Cancer Centerand New York Blood Centerlearn More At Http Www Targazyme Com
